



## **Eiger BioPharmaceuticals to Present at Jefferies 2017 Global Healthcare Conference June 7th**

PALO ALTO, Calif., May 30, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory, President and CEO of Eiger, will present a corporate overview and business update at the Jefferies 2017 Global Healthcare Conference at 11:00 am ET on Wednesday, June 7, 2017, in New York City.

Eiger will also host one-on-one meetings with investors at the Jefferies 2017 Global Healthcare Conference on Wednesday, June 7, 2017.

### **About Eiger**

Eiger is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare diseases. The company has built a diverse portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which an effective therapy is urgently needed. For additional information about Eiger and its clinical programs, please visit [www.eigerbio.com](http://www.eigerbio.com).

Investors: Ingrid Choong, PhD, Eiger BioPharmaceuticals, Inc., 650-619-6115, [ichoong@eigerbio.com](mailto:ichoong@eigerbio.com)

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-present-at-jefferies-2017-global-healthcare-conference-june-7th-300465146.html>

SOURCE Eiger BioPharmaceuticals, Inc.

